News
All NewsBlogs
Media
All VideosCase-Based Roundtable SeriesEichenbaum AcornsExpert InterviewsEyeviewsInsightsMedical World NewsPodcastsRapid ReadoutsThe Retina TL;DRViewpoints
Conference
Conference CoverageConference Listing
Publications
Modern Retina Digital EditionSupplements And Featured Publications
More
Resources
Between the LinesCME/CEEYLEA 8mg for nAMD and DME TreatmentSponsored Resources
Partners

Subscribe

  • News
  • Media
  • Conference
  • Publications
  • Resources
  • Partners
  • Subscribe
  • AMD
    • Wet AMD
  • Biosimilar
  • Diabetic Macular Edema
    • Diabetic Eye Awareness
  • Diabetic Retinopathy
  • Geographic Atrophy
  • Imaging
  • Inherited Retinal Diseases
  • Ophthalmology
    • Europe
  • RVO
  • Retina Technology
  • Retinal Surgery
  • Uveitis
Spotlight -
Geographic Atrophy
Advertisement

Eric B. Suhler, MD, MPH

Advertisement

Articles by Eric B. Suhler, MD, MPH

Adalimumab therapy safe, effective in real-world, open-label uveitis study

ByFred Gebhart,Eric B. Suhler, MD, MPH
May 1st 2018
Advertisement

Latest Updated Articles

  • Adalimumab therapy safe, effective in real-world, open-label uveitis study
    Adalimumab therapy safe, effective in real-world, open-label uveitis study

    Published: May 1st 2018 | Updated:



Advertisement
Advertisement

Trending on Modern Retina

1

Q&A: The ARCHER trial and the importance of continued GA research

2

Frank Holz, MD, FEBO, FARVO, highlights new treatment developments at EURETINA

3

Q&A: What is the value of the YOURS program at EURETINA?

4

Challenges Reported by Young Physicians in Managing Geographic Atrophy and How these Shape Patient Care

  • About
  • Advertise
  • Editorial
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us